AMLX (Amylyx Pharmaceuticals) PS Ratio: (As of Jun. 30, 2026)


AMLX Amylyx Pharmaceuticals Inc AMLX
33 GF Score
Price $17.96
! 3 Warning Signs
View Full Analysis

What is Amylyx Pharmaceuticals PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Amylyx Pharmaceuticals's share price is $17.96. Amylyx Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00. Hence, Amylyx Pharmaceuticals's PS Ratio for today is .

The historical rank and industry rank for Amylyx Pharmaceuticals's PS Ratio or its related term are showing as below:

During the past 7 years, Amylyx Pharmaceuticals's highest PS Ratio was 6538.33. The lowest was 0.29. And the median was 3.22.

AMLX's PS Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.205
* Ranked among companies with meaningful PS Ratio only.

Amylyx Pharmaceuticals's Revenue per Sharefor the three months ended in Mar. 2026 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00.

Back to Basics: PS Ratio


Amylyx Pharmaceuticals  (NAS:AMLX) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Amylyx Pharmaceuticals PS Ratio Related Terms


Amylyx Pharmaceuticals PS Ratio Historical Data

* Premium members only.

The historical data trend for Amylyx Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amylyx Pharmaceuticals PS Ratio Chart

Amylyx Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PS Ratio
Get a 7-Day Free Trial 0.00 97.24 2.71 2.95 0.00

Amylyx Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AMLX vs ANIP, TRLV, PBH: PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Amylyx Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amylyx Pharmaceuticals PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amylyx Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where Amylyx Pharmaceuticals's PS Ratio falls into.


AMLX
33GF Score
Amylyx Pharmaceuticals Inc AMLX
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amylyx Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Amylyx Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=17.96/0
=

Amylyx Pharmaceuticals's Share Price of today is $17.96.
Amylyx Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Amylyx Pharmaceuticals Business Description

Address 55 Cambridge Parkway, Suite 6W, Cambridge, MA, USA, 02142
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
33GF Score

Get the complete analysis for AMLX

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.96
Price